1. Academic Validation
  2. Design and biological evaluation of dual tubulin/HDAC inhibitors based on millepachine for treatment of prostate cancer

Design and biological evaluation of dual tubulin/HDAC inhibitors based on millepachine for treatment of prostate cancer

  • Eur J Med Chem. 2024 Mar 15:268:116301. doi: 10.1016/j.ejmech.2024.116301.
Shanshan Xie 1 Jiafu Leng 1 Shifang Zhao 1 Liqiao Zhu 1 Mengyu Zhang 1 Mengdan Ning 1 Bo Zhao 1 Lingyi Kong 2 Yong Yin 3
Affiliations

Affiliations

  • 1 Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
  • 2 Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 210009, People's Republic of China. Electronic address: cpu_lykong@126.com.
  • 3 Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 210009, People's Republic of China. Electronic address: yongyin@cpu.edu.cn.
Abstract

In this work, a novel of dual tubulin/HDAC inhibitors were designed and synthesized based on the structure of natural product millepachine, which has been identified as a tubulin polymerization inhibitor. Biological evaluation revealed that compound 9n exhibited an impressive potency against PC-3 cells with the IC50 value of 16 nM and effectively inhibited both microtubule polymerization and HDAC activity. Furthermore, compound 9n not only induced cell cycle arrest at G2/M phase, but also induced PC- 3 cells Apoptosis. Further study revealed that the induction of cell Apoptosis by 9n was accompanied by a decrease in mitochondrial membrane potential and an elevation in Reactive Oxygen Species levels in PC-3 cells. Additionally, 9n exhibited inhibitory effects on tumor cell migration and angiogenesis. In PC-3 xenograft model, 9n achieved a remarkable tumor inhibition rate of 90.07%@20 mg/kg, significantly surpassing to that of CA-4 (55.62%@20 mg/kg). Meanwhile, 9n exhibited the favorable drug metabolism characteristics in vivo. All the results indicate that 9n is a promising dual tubulin/HDAC Inhibitor for chemotherapy of prostate Cancer, deserving the further investigation.

Keywords

Antitumor; HDAC; Millepachine; Tubulin.

Figures